CVKD Stock Analysis: Buy, Sell, or Hold?
CVKD - Cadrenal Therapeutics, Inc. Common Stock
$3.33
-0.37 (-10.00%)
▼
5d:
-20.9%
30d:
-36.81%
90d:
-55.75%
HOLD
MODERATE Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Get Alerted When CVKD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CVKD shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CVKD shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CVKD is currently trading at $3.33, which is considered oversold relative to its 30-day fair value range of $4.12 to $5.35.
Technical Outlook: Technically, CVKD is in a strong downtrend. The price is currently testing key support at $3.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.0% recently.
Market Sentiment: CVKD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $27.67 (+730.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CVKD is in a strong downtrend. The price is currently testing key support at $3.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.0% recently.
Market Sentiment: CVKD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $27.67 (+730.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.12 -
$5.35
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.0%)
- BULLISH: Trading 730.8% below Wall St target ($27.67)
- CAUTION: 5-day price weakness (-20.9%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$4.12 -
$5.35
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.80
Resistance Level
$5.02
Current Trend
Strong Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.85
Wall Street Target
$27.67
(+730.8%)
Share & Embed Analysis
Last updated: June 16, 2026 3:58 AM ET
Data refreshes hourly during market hours. Next update: 4:58 AM
Data refreshes hourly during market hours. Next update: 4:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CVKD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Matthew K Szot
SELL
9933 shares
2025-12-29
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 50 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$275 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$103 | 58 HOLD |
